定期ワクチンが認知症リスクを低減か、専門家が驚きの仮説提示 Routine vaccines may cut dementia risk—experts have startling hypothesis on how

A growing body of research suggests that routine vaccinations, particularly the shingles vaccine, may be associated with a reduced risk of developing dementia later in life. If this link proves causal, it could represent a significant new avenue for dementia prevention using tools that are already widely available and well understood.

Several large-scale epidemiological studies in recent years have found that older adults who received the shingles vaccine show notably lower rates of dementia compared with unvaccinated peers. A particularly compelling natural experiment in Wales exploited an age-based cutoff for vaccine eligibility, allowing researchers to compare otherwise similar populations. The vaccinated group showed roughly a 20% reduction in dementia incidence. Similar associations have been reported for influenza vaccines and the tetanus-diphtheria combination, suggesting the effect may not be confined to one pathogen.

Experts have offered several hypotheses to explain the connection. One centers on neurotropic viruses like varicella-zoster (VZV), which lie dormant in nerve tissue and can reactivate later in life. Reactivation may trigger neuroinflammation and amyloid-beta accumulation, both implicated in Alzheimer's pathology. By suppressing reactivation, vaccines could reduce these triggers. A second, more startling hypothesis is that vaccines exert a broader "training" effect on the immune system, dampening chronic inflammation and autoimmune responses that erode brain health over time.

The broader context matters here. Alzheimer's research has increasingly looked beyond the dominant amyloid hypothesis toward infection- and inflammation-based models. Studies linking herpes simplex virus type 1 (HSV-1) to cognitive decline, and others tying periodontal bacteria to brain pathology, have added weight to the idea that pathogens play a role in neurodegeneration. Meanwhile, newly approved anti-amyloid antibody drugs like lecanemab offer only modest benefits with notable side effects, sharpening interest in preventive strategies.

Important caveats remain. Most of the evidence comes from observational studies, where confounding factors are hard to eliminate. People who get vaccinated tend to be more health-conscious, exercise more, and access healthcare more regularly, all of which independently affect dementia risk. Establishing causality will require randomized controlled trials or further quasi-experimental designs. Still, the possibility that safe, inexpensive, and widely deployed vaccines could carry secondary benefits for brain health carries significant implications for public health policy, particularly as aging populations face a rising dementia burden worldwide.